Detalhe da pesquisa
1.
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Ann Oncol
; 23(9): 2341-2346, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22367707
2.
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Ann Oncol
; 21(3): 535-539, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19850635
3.
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Colorectal Dis
; 11(3): 264-9, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18573119
4.
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Ann Oncol
; 19(6): 1154-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18281265
5.
Ultrasound elastography in patients with rectal cancer treated with chemoradiation.
Eur J Radiol
; 82(6): 913-7, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23410908